Pharmaceutical

Kyowa Kirin gets grant for monoclonal antibody inhibiting ccr1 activation by ccl15

Discover the groundbreaking patent by Kyowa Kirin Co Ltd for a monoclonal antibody targeting CCR1, inhibiting its activation by CCL15. Explore the therapeutic and diagnostic potential for CCR1-related diseases.

Apr 11, 2024 - 00:00
Discover the groundbreaking patent by Kyowa Kirin Co Ltd for a monoclonal antibody targeting CCR1, inhibiting its activation by CCL15. Explore the therapeutic and diagnostic potential for CCR1-related diseases.
Read the original article

Tags:

Previous Article

ADMA Biologics gets grant for treatment of upper respiratory tract infection wit...

Next Article

Dynamic-EC: An efficient dynamic erasure coding method for permissioned blockcha...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

A broad range of unmet needs remains in the immuno-oncology space

A broad range of unmet needs remains in the immuno-onco...

May 2, 2023

STAT+: Pharmalittle: U.K. regulator to streamline clinical trial approvals; NIH won’t seize patents to cut price of cancer drug

STAT+: Pharmalittle: U.K. regulator to streamline clini...

Mar 22, 2023

Mabwell’s 9MW2821 gains FDA fast track status for breast cancer

Mabwell’s 9MW2821 gains FDA fast track status for breas...

Jul 16, 2024